Biogen and Sage Therapeutics Collaboration Concludes
In a notable shift within the biotech arena, Sage Therapeutics Inc has disclosed that Biogen Inc has officially ended its collaboration and licensing agreement concerning the SAGE-324 program. This decision arrives in the wake of recent Phase 2 KINETIC 2 study results that were disappointing for the chronic treatment of essential tremor (ET).
Negative Results from KINETIC 2 Study
The collaborative KINETIC 2 study aimed to evaluate the dose-response relationship of SAGE-324 for ET, a neurological disorder characterized by involuntary trembling in various body parts. Sadly, the study results did not meet expectations, indicating no statistically significant dose-response relationship, particularly concerning the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 total score.
Understanding Essential Tremor
Essential tremor can dramatically affect individuals' daily lives, making simple tasks such as writing or holding objects difficult. The implications of such a disorder can be far-reaching, influencing both mental and emotional health. The recent study's failure signals a need for continued exploration of alternative treatment pathways for those impacted by the condition.
Impact on SAGE-324 Development
In light of the setbacks, Sage Therapeutics and Biogen will discontinue the ongoing open-label safety study for the investigational drug SAGE-324 in ET, with no plans for future clinical development in this area. From the date of termination, set for February 17, 2025, Sage will regain full ownership of the SAGE-324 asset and evaluate other potential indications where the compound may be beneficial.
Future Considerations for Sage Therapeutics
Despite the cessation of SAGE-324 development for essential tremor, Sage Therapeutics remains proactive in exploring additional treatment avenues. Their commitment to advancing psychiatric and neurological healthcare is unwavering, and innovative solutions are still within reach.
Continued Partnership on Zurzuvae
Interestingly, amidst this collaboration termination, Biogen and Sage Therapeutics will continue to work together on Zurzuvae (zuranolone), recognized as the first FDA-approved oral treatment aimed at addressing postpartum depression. This collaboration represents a significant effort in enhancing mental health solutions, highlighting the companies' dedication to tackling pressing healthcare needs.
Market Reaction and Stock Performance
On the market front, the recent developments have seen a positive trend in stock prices. As per the latest updates, SAGE stock rose by 1.42%, trading at $7.12, while BIIB stock saw an increase of 1.77% to $192.42. This market optimism suggests investor confidence despite the challenges faced by the companies.
Frequently Asked Questions
What prompted the end of the collaboration between Biogen and Sage Therapeutics?
The collaboration was terminated due to disappointing results from the Phase 2 KINETIC 2 study for SAGE-324, which did not show a statistically significant effect for treating essential tremor.
What is SAGE-324, and what condition was it being developed for?
SAGE-324 is an investigational treatment that was being evaluated for its effectiveness in treating essential tremor, a neurological condition characterized by involuntary shaking.
Will Sage Therapeutics continue to develop SAGE-324?
While development for SAGE-324 in essential tremor will cease, Sage Therapeutics plans to explore other potential indications for the compound.
What other products do Biogen and Sage Therapeutics collaborate on?
The two companies will continue their collaboration on Zurzuvae (zuranolone), an FDA-approved oral treatment for postpartum depression.
How did the stock market react to this news?
Following the announcement, SAGE stock increased by 1.42%, trading at $7.12, while BIIB stock rose 1.77%, reaching $192.42, suggesting a positive response from investors.
